Authors
Latest:
Dr. Yang on Resistance Mechanisms from Osimertinib in NSCLCJames CH Yang, MD, PhD, Professor of Medicine, Deputy Director, Department of Medical Oncology, National Taiwan University Hospital, Director, Cancer Research, Center National Taiwan University College of Medicine, discusses resistance mechanisms that develop from treatment with osimertinib (Tagrisso) and other EGFR tyrosine kinase inhibitors (TKIs). Yang discussed this in an interview during the 2018 European Lung Cancer Congress, which is a joint collaboration between ESMO and the IASLC.
Latest:
eContour: Evidence-Based Interactive Contouring Resources at the Point of CareeContour is a novel, web-based, interactive contouring resource that aims to facilitate access to decision support through high-yield radiation treatment recommendations that are free and available at the point of care.
Latest:
Dr. Hoffman Discusses Challenges in Relapsed/Refractory MyelomaJames E. Hoffman, MD, assistant professor of clinical medicine at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses remaining challenges in the field of relapsed/refractory myeloma.
Latest:
Surviving the MarathonA chance encounter while running an ultramarathon energized James Gerson, MD, to finish the race, and fueled his devotion and compassion afterward.
Latest:
Dr. Gulley on Take Home Message With Olaparib Plus Durvalumab in mCRPCJames Gulley, MD, PhD, chief, Genitourinary Malignancies Branch, and director, Medical Oncology Service at the National Cancer Institute, discusses the take-home message with the combination of olaparib (Lynparza) plus durvalumab (Imfinzi) in metastatic castration-resistant prostate cancer.
Latest:
Dr. Geller on Renal Rhabdoid Tumors in Pediatric PatientsJames I. Geller, MD, medical director, Kidney and Liver Tumors Program, Cincinnati Children’s Hospital Medical Center, discusses renal rhabdoid tumors in pediatric patients.
Latest:
Dr Harding on the FDA Approval of Zanidatamab for HER2+ Biliary Tract CancerJames J. Harding, MD, discusses the significance of the FDA approval of zanidatamab for pretreated, unresectable or metastatic HER2+ biliary tract cancer.
Latest:
Dr. Hsieh on Patient Characterization From RECORD-3 Study in Metastatic RCCJames J. Hsieh, MD, medical oncologist, physician-scientist, Memorial Sloan Kettering Cancer Center, discusses overall survival results in the RECORD-3 study based on 3 distinct clear cell metastatic renal cell carcinoma molecular subgroups.
Latest:
Dr. Hsieh on Unmet Needs of Rare Kidney Cancer VariantsJames J. Hsieh, MD, PhD, discusses unmet needs in non-clear cell renal cell carcinoma.
Latest:
Dr. James Lee on Overcoming Mismatched Repair in Colorectal CancerJames J. Lee, MD, PhD, Assistant Professor of Medicine, Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, discusses mismatched repair in colorectal cancer.
Latest:
Evolving Treatment Landscape of MyelofibrosisClosing out their discussion on myelofibrosis management, experts from the John Theurer Cancer Center consider novel therapies under investigation and the future treatment paradigm.
Latest:
Dr. Kearns on AEs Associated With Surgery in Prostate CancerJames Kearns, MD, assistant professor of medicine, Levine Cancer Institute, discusses adverse events associated with surgery in patients with high-risk prostate cancer.
Latest:
Dr. Godwin on Immunotherapy Efforts in Prostate CancerJames L. Godwin, MD, physician, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses immunotherapy efforts in prostate cancer.
Latest:
Dr Gulley on the Investigation of PRGN-2009 Plus Bintrafusp Alfa in HPV-Associated CancersJames L. Gulley, MD, PhD, discusses a phase 1 trial of PRGN-2009 alone and in combination with bintrafusp alfa in patients with recurrent and/or metastatic HPV-associated cancers.
Latest:
New Test Could Guide More Precise Treatment of GVHDA new test reveals which patients with leukemia and other blood disorders are likely to respond to treatment for graft-versus-host disease that develops after a stem cell transplant.
Latest:
Dr. Mohler on Recommendations for Genetic Testing in Prostate CancerJames L. Mohler, MD, professor of oncology, associate director, and senior vice president of Translational Research, chief of Inter-Institutional Academics at Roswell Park Comprehensive Cancer Center, discusses recommendations for performing genetic testing in prostate cancer.
Latest:
Dr. Mulshine Discusses New Recommendations for Lung Cancer ScreeningJames L. Mulshine, MD, professor, Associate Provost for Research, Vice President, Rush University Medical Center discusses new USPSTF recommendations for lung cancer screening.
Latest:
Dr. Larkin on Lenvatinib Plus Everolimus in Patients With RCCJames Larkin, MD, PhD, medical oncologist, Royal Marsden Hospital, discusses a phase II study that examined the combination of lenvatinib and everolimus versus either agent alone in patients with renal cell carcinoma.
Latest:
Dr. Larner on Integrating Radiation Therapy With Immune Checkpoint Blockade in NSCLCJames Larner, MD, professor and chair of Radiation Oncology, University of Virginia Health System, discusses integrating radiation therapy with immune checkpoint blockade in patients with non–small cell lung cancer (NSCLC).
Latest:
BRAF-Mutated Colorectal Cancer: Early Frustrations and Future OptimismThis review highlights that preclinical data and discusses several ongoing clinical trials that are leveraging this information to explore new therapeutic strategies in targeting BRAF-mutated colorectal cancer.
Latest:
Acute Myeloid Leukemia: Trial Data From the ASCO and EHA 2023 Annual MeetingsFollowing the ASCO 2023 and EHA 2023 Annual Meetings, experts discuss important updates in acute myeloid leukemia.
Latest:
The Search for Biomarkers in Metastatic Breast CancerJames M. Reuben, PhD, MBA, discusses the search for biomarkers in patients with metastatic breast cancer.
Latest:
Dr. Rossetti on the Utility of JAK Inhibitors in MPNsJames M. Rossetti, DO, discusses the utility of JAK inhibitors in myeloproliferative neoplasms.
Latest:
Dr. Melotek on Cetuximab Added to Chemotherapy and Chemoradiation in Head and Neck CancerJames Melotek, MD, Radiation and Cellular Oncology, University of Chicago Medicine, discusses an analysis of a phase II study examining the addition of cetuximab to induction chemotherapy and accelerated or hyperfractionated chemoradiation therapy for locoregionally advanced head and neck cancer.
Latest:
Dr. Mohler on Guidelines for Recording Family History in Prostate CancerJames Mohler, MD, discusses what information should be included in a family history, based on the updated National Comprehensive Cancer Network guidelines for genetic testing in prostate cancer.
Latest:
Dr. Gerson on Clinical Trial Accrual in MCLJames N. Gerson, MD, discusses clinical trial accrual in mantle cell lymphoma.
